[ad_1]
DUBLIN – (COMMERCIAL THREAD) – The report “Dermatology CRO market size, share and trend analysis report by type (preclinical, clinical, drug discovery), by department (clinical oversight, regulatory / medical affairs), by region and segment forecast, 2021-2028 â€has been added to ResearchAndMarkets.com offer.
The global dermatology CRO market size is expected to reach USD 7.04 billion by 2028. It is expected to grow at a CAGR of 6.9% from 2021 to 2028.
The increased demand for topical dermatological drugs, such as anti-inflammatory, anti-infective, local anesthetics, cleansers and emollients, to treat acne is a major factor driving the market. In addition, an increased awareness of skin diseases, a strong demand for rapid diagnosis, and an increase in the prevalence of skin cancer and other skin problems are all driving the industry forward.
The COVID-19 pandemic has rocked the economy in 2020 and is having a continuing impact on various industries across the world. The dermatology contract research organization (CRO) market has been little affected by the repercussions of the pandemic due to the emergence of virtual clinical trials and government initiatives to support disrupted supply chains in the world. the field of health care. Additionally, with ongoing vaccination campaigns and the lifting of shelter-in-place mandates, the clinical trial bottleneck is improving. So the future looks good for the market.
Factors such as increased investment in R&D programs, a preference for outsourcing tasks due to time and cost constraints, and the expiration of patents in the dermatology industry are just a few. key factors that are expected to drive the market over the forecast period. Contract research outsourcing collaborations provide cutting edge services, so pharmaceutical players and government agencies prefer to delegate projects to dermatology CROs, allowing the market to grow.
Highlights of the Dermatology CRO Market Report
-
On the basis of type, the clinical segment captured the largest revenue share of over 75.0% in 2020 due to advancements in technology, the globalization of clinical trials and the need for dermatology CROs to conduct research. clinical tests.
-
In the clinical-type segment, the phase III segment accounted for the largest share of revenue of over 50.0% in 2020, as phase III clinical trials are the most expensive and involve a large patient base.
-
By department, clinical surveillance held the largest share of revenue in 2020 due to an increase in the number of clinical trials and the need to monitor these trials effectively.
-
Asia Pacific captured the largest revenue share of over 40.0% in 2020. This is due to the high prevalence of skin disorders, diverse populations, ease with which patients can be recruited and retained and improving the regulatory framework.
Company Profiles:
-
IQVIA
-
Covance, Inc.
-
Pharmaceutical Product Development, Inc.
-
International Parexel Company
-
Charles River International Laboratories, Inc.
-
Icon, Plc
-
Syneos Health
-
Wuxi Apptec
-
Bioskin
-
Proinnovera
For more information on this report, visit https://www.researchandmarkets.com/r/ofyy85
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for market research reports and international market data. We provide you with the latest data on international and regional markets, key industries, major companies, new products and the latest trends.
[ad_2]
